Articles by Michael D. Lam - Pharmaceutical Executive

ADVERTISEMENT

Articles by Michael D. Lam

Online Meetings: Teleconferencing, Meet the Dodo

Web meetings are gaining, but not at the expense of live ones.
Mar 1, 2005

Virtual get-togethers, while still a small element of the meeting universe, are growing fast. In 2004, web-based meetings across all industries generated $600 million in revenues. That figure is expected to grow at an annual rate of 30 percent for the near-term, says Bob Maiden, president of The Maxwell Group, a provider of live, direct-to-physician web conferencing services.

Magic Molecules

Pipeline Report
Dec 1, 2004

Pharm Exec's Pipeline Report is packed with 25 of the year's most eye-catching experimental drugs. What's their secret? No smoke or mirrors—just innovative science, therapeutic value, and good business sense.

AfterShoxx

Merck's withdrawal of blockbuster Vioxx blew a $2.5 billion hole in its revenues and stirred up a storm of suspicion and speculation accompanied by a chorus of wild laments. Some perspective, anyone?
Nov 1, 2004

We didn't think, even before Vioxx got pulled, that Arcoxia would ever get approved because we thought it had cardiovascular signals—and because of the debate over Vioxx for the last five years. Now, unequivocally, we don't believe it will be approved.

Spend Trends: A $20 Billion Bill and Plenty of Change

Sep 1, 2004

Pharma marketing appears to operate in a world of its own. When US ad expenditures dipped in 2001, pharma's spend marched steadily on. (See "A Different Drum.") Now, as the ad industry celebrates the quadrennial coincidence of the Olympics and the US presidential campaign, is pharma taking notice? "Not really," says Anne Devereaux, chief integration officer at BBDO.

How to Win Friends, Influence People, and Make NMEs

Wyeth has quadrupled its discovery output while holding resources steady. Its secret? Really no secret at all.
Aug 1, 2004

Wyeth once made Jiffy Pop and shoe polish. Now the company is promising to deliver two new molecular entities every year.

Stop Giving Away Your Secrets

Big pharma companies aggressively gather sensitive intelligence about their competitors, but few, strangely, make a systematic effort to protect their own.
Jul 1, 2004

Big pharma companies aggressively gather sensitive intelligence about their competitors, but few, strangely, make a systematic effort to protect their own.

Why Alliances Fail

Most biotech-pharma alliances fall short of expectations. But are they doomed -- or just difficult? In this second of two parts, experts say strategic partnerships offer acceptable odds, but only if you know what you're doing.
Jun 1, 2004

Our industry can succeed only by collaborations," a biotech CEO recently told Pharm Exec, "because no company has the whole of the jigsaw complete -- only a piece." Clearly many of his pharma counterparts agree. The web of alliances formed by the top two dozen biotech and pharma companies from 1973 to 2001 -- at least the 12,500 contracts made public by these firms -- is as tightly knit as a linen shirt.

Dangerous Liaisons

Why do most biotech–pharma alliances fail? The answer, in this first of two parts, begins with the messy reality of corporate relationships. Two case histories demonstrate the good, the bad, and the ugly side of strategic partnering.
May 1, 2004

Alliances are a favorite of corporate strategists everywhere. More than 10,000 interfirm collaborations were formed worldwide in 2000, double the number of five years before. Alliances now generate 25 percent of the top 1,000 public US companies' revenues, up from 7 percent in 1990.

Is Everyone a Target?

A new legal theory, the latest off-label commotion, appears far-fetched to some, but raises a few serious questions. Here's one:
Mar 1, 2004

Pfizer is embroiled in a whistleblower lawsuit based on an unproven legal theory with the potential "to scare the hell out of a lot of drug companies," says attorney Alan Minsk of Arnall Golden Gregory. If upheld, even those compliant with FDA regulations for off-label promotion might still be liable for Medicaid fraud under the federal False Claims Act (FCA).

ADVERTISEMENT

Click here